fbpx

Female Sexual Dysfunction Pipeline Review, H1 2018 – ResearchAndMarkets.com

The “Female
Sexual Dysfunction – Pipeline Review, H1 2018” report has been
added to ResearchAndMarkets.com’s offering.

Female Sexual Dysfunction – Pipeline Review, H1 2018, provides
comprehensive information on the therapeutics under development for
Female Sexual Dysfunction (Women’s Health), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Female Sexual Dysfunction (Women’s Health) pipeline guide also
reviews of key players involved in therapeutic development for Female
Sexual Dysfunction and features dormant and discontinued projects. The
guide covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Pre-Registration,
Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages
are 1, 2, 6, 1, 5, 2 and 1 respectively.

Female Sexual Dysfunction (Women’s Health) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/research/q8wm98/female_sexual?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618006152/en/